Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Furthermore, just this week the FDA removed tirzepatide -- the main ingredient in Mounjaro and Zepbound -- from its shortage ...

Tirzepatide may be more effective than semaglutide in helping people lose weight. At least that's the findings from recent ...

Losing weight on a GLP-1 can lead to muscle loss, research shows. Here, obseity experts share how to preserve your lean ...

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Zepbound and Lilly's widely used diabetes drug, Mounjaro, both chemically called tirzepatide, belong to a class of drugs ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...